Cargando…

Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial

BACKGROUND: The aim of the study was to evaluate the efficacy of nicorandil and alprostadil on myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI). METHODS: In this prospective, single-blinded, randomized controlled study, 90 consecutive patients scheduled...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Weifeng, Dai, Jinjie, Zheng, Xiaowen, Xu, Ke, Yang, Xiaoxiao, Shen, Lan, Wang, Xiaolei, Hao, Ziyong, Qiu, Xingbiao, Jiang, Lisheng, Shi, Hongyu, Shen, Linghong, He, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052047/
https://www.ncbi.nlm.nih.gov/pubmed/33847683
http://dx.doi.org/10.1097/MD.0000000000025551
_version_ 1783679852631556096
author Zhang, Weifeng
Dai, Jinjie
Zheng, Xiaowen
Xu, Ke
Yang, Xiaoxiao
Shen, Lan
Wang, Xiaolei
Hao, Ziyong
Qiu, Xingbiao
Jiang, Lisheng
Shi, Hongyu
Shen, Linghong
He, Ben
author_facet Zhang, Weifeng
Dai, Jinjie
Zheng, Xiaowen
Xu, Ke
Yang, Xiaoxiao
Shen, Lan
Wang, Xiaolei
Hao, Ziyong
Qiu, Xingbiao
Jiang, Lisheng
Shi, Hongyu
Shen, Linghong
He, Ben
author_sort Zhang, Weifeng
collection PubMed
description BACKGROUND: The aim of the study was to evaluate the efficacy of nicorandil and alprostadil on myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI). METHODS: In this prospective, single-blinded, randomized controlled study, 90 consecutive patients scheduled for elective PCI for de novo coronary lesions were assigned to the nicorandil, alprostadil, and nitroglycerin groups in a 1:1:1 ratio. Drugs were administered intracoronary via a targeted perfusion microcatheter. The primary endpoint was the thrombolysis in myocardial infarction (TIMI) myocardial perfusion frame count (TMPFC). Additionally, the corrected TIMI frame count (cTFC), TIMI myocardial perfusion grade (TMPG), and incidence of periprocedural myocardial injury (PMI) were assessed. RESULTS: Both nicorandil and alprostadil were significantly effective in reducing TMPFC (114.6 ± 33.7 vs 93.4 ± 30.9, P = .016; 114.3 ± 34.3 vs 94.7 ± 33.3, P = .029, respectively). Similar findings were observed in the improvement of cTFC (20.3 ± 10.5 vs 13.5 ± 5.0, P = .003; 20.2 ± 7.4 vs 15.2 ± 5.2, P = .003, respectively) and percentage of TMPG 3 (100% vs 82.8%, P = .052; 83.3% vs 96.7%, P = .196, respectively); whereas, nitroglycerin produced a limited effect on TMPFC (114.4 ± 30.9 vs 112.1 ± 31.9, P = .739), cTFC (19.4 ± 7.2 vs 19.3 ± 7.2, P = .936), and percentage of TMPG 3 (86.7% vs 86.7%, P = 1.000). No significant difference was found in the incidence of PMI (16.7% vs 16.0% vs 27.6%, P = .537), though it was comparatively lower in the nicorandil and alprostadil groups. Furthermore, the intracoronary administration of nicorandil and alprostadil had a mild effect on blood pressure and heart rate. CONCLUSIONS: The intracoronary administration of nicorandil and alprostadil via a targeted perfusion microcatheter was more effective in improving myocardial perfusion in patients undergoing elective PCI than nitroglycerin.
format Online
Article
Text
id pubmed-8052047
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-80520472021-04-19 Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial Zhang, Weifeng Dai, Jinjie Zheng, Xiaowen Xu, Ke Yang, Xiaoxiao Shen, Lan Wang, Xiaolei Hao, Ziyong Qiu, Xingbiao Jiang, Lisheng Shi, Hongyu Shen, Linghong He, Ben Medicine (Baltimore) 3400 BACKGROUND: The aim of the study was to evaluate the efficacy of nicorandil and alprostadil on myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI). METHODS: In this prospective, single-blinded, randomized controlled study, 90 consecutive patients scheduled for elective PCI for de novo coronary lesions were assigned to the nicorandil, alprostadil, and nitroglycerin groups in a 1:1:1 ratio. Drugs were administered intracoronary via a targeted perfusion microcatheter. The primary endpoint was the thrombolysis in myocardial infarction (TIMI) myocardial perfusion frame count (TMPFC). Additionally, the corrected TIMI frame count (cTFC), TIMI myocardial perfusion grade (TMPG), and incidence of periprocedural myocardial injury (PMI) were assessed. RESULTS: Both nicorandil and alprostadil were significantly effective in reducing TMPFC (114.6 ± 33.7 vs 93.4 ± 30.9, P = .016; 114.3 ± 34.3 vs 94.7 ± 33.3, P = .029, respectively). Similar findings were observed in the improvement of cTFC (20.3 ± 10.5 vs 13.5 ± 5.0, P = .003; 20.2 ± 7.4 vs 15.2 ± 5.2, P = .003, respectively) and percentage of TMPG 3 (100% vs 82.8%, P = .052; 83.3% vs 96.7%, P = .196, respectively); whereas, nitroglycerin produced a limited effect on TMPFC (114.4 ± 30.9 vs 112.1 ± 31.9, P = .739), cTFC (19.4 ± 7.2 vs 19.3 ± 7.2, P = .936), and percentage of TMPG 3 (86.7% vs 86.7%, P = 1.000). No significant difference was found in the incidence of PMI (16.7% vs 16.0% vs 27.6%, P = .537), though it was comparatively lower in the nicorandil and alprostadil groups. Furthermore, the intracoronary administration of nicorandil and alprostadil had a mild effect on blood pressure and heart rate. CONCLUSIONS: The intracoronary administration of nicorandil and alprostadil via a targeted perfusion microcatheter was more effective in improving myocardial perfusion in patients undergoing elective PCI than nitroglycerin. Lippincott Williams & Wilkins 2021-04-16 /pmc/articles/PMC8052047/ /pubmed/33847683 http://dx.doi.org/10.1097/MD.0000000000025551 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 3400
Zhang, Weifeng
Dai, Jinjie
Zheng, Xiaowen
Xu, Ke
Yang, Xiaoxiao
Shen, Lan
Wang, Xiaolei
Hao, Ziyong
Qiu, Xingbiao
Jiang, Lisheng
Shi, Hongyu
Shen, Linghong
He, Ben
Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
title Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
title_full Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
title_fullStr Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
title_full_unstemmed Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
title_short Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
title_sort myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: a randomized controlled trial
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052047/
https://www.ncbi.nlm.nih.gov/pubmed/33847683
http://dx.doi.org/10.1097/MD.0000000000025551
work_keys_str_mv AT zhangweifeng myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT daijinjie myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT zhengxiaowen myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT xuke myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT yangxiaoxiao myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT shenlan myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT wangxiaolei myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT haoziyong myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT qiuxingbiao myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT jianglisheng myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT shihongyu myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT shenlinghong myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial
AT heben myocardialprotectiveeffectofintracoronaryadministrationofnicorandilandalprostadilviatargetedperfusionmicrocatheterinpatientsundergoingelectivepercutaneouscoronaryinterventionarandomizedcontrolledtrial